Literature DB >> 9570133

The ETS-domain transcription factor family.

A D Sharrocks1, A L Brown, Y Ling, P R Yates.   

Abstract

During recent years, several significant discoveries have been made concerning the function of ETS-domain transcription factors. This family of transcription factors was originally defined on the basis of the conserved primary sequence of their DNA-binding domains. The ETS DNA-binding domain is also conserved at the structural level and is a divergent member of the winged helix-turn-helix superfamily of DNA binding proteins. This sequence conservation is reflected by their overlapping DNA-binding specificities based on the central GGAA/T motif. In addition to DNA-protein interactions, protein-protein interactions with partner proteins often play major roles in targeting ETS-domain proteins to specific promoters. Several such partner proteins have been identified. ETS-domain proteins function as either transcriptional activators or repressors and their activities are often regulated by signal transduction pathways, including the MAP kinase pathways. Specific links between such pathways and ETS-domain proteins have been established in several different experimental systems. ETS-domain transcription factors regulate a diverse array of biological functions including mammalian haematopoiesis and Drosophila eye development. In vertebrates, many ETS-domain proteins regulate embryonic and adult haematopoiesis. Deregulation of ETS-domain protein activity often leads to tumorigenesis. Future work will uncover further details of how these transcription factors work at the molecular level to regulate specific biological processes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9570133     DOI: 10.1016/s1357-2725(97)00086-1

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  86 in total

1.  The mechanism of complex formation between Fli-1 and SRF transcription factors.

Authors:  P Dalgleish; A D Sharrocks
Journal:  Nucleic Acids Res       Date:  2000-01-15       Impact factor: 16.971

2.  Do lampreys have lymphocytes? The Spi evidence.

Authors:  S Shintani; J Terzic; A Sato; M Saraga-Babic; C O'hUigin; H Tichy; J Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 3.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

4.  Regulation of gene expression by internal ribosome entry sites or cryptic promoters: the eIF4G story.

Authors:  Baoguang Han; Jian-Ting Zhang
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

5.  Functional analysis of the transcription factor ER71 and its activation of the matrix metalloproteinase-1 promoter.

Authors:  Luciano De Haro; Ralf Janknecht
Journal:  Nucleic Acids Res       Date:  2002-07-01       Impact factor: 16.971

6.  Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1).

Authors:  T L Gu; T L Goetz; B J Graves; N A Speck
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

7.  Auto-inhibition of Ets-1 is counteracted by DNA binding cooperativity with core-binding factor alpha2.

Authors:  T L Goetz; T L Gu; N A Speck; B J Graves
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 8.  Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies.

Authors:  Mandeep S Tamber; Krishan Bansal; Muh-Lii Liang; Todd G Mainprize; Bodour Salhia; Paul Northcott; Michael Taylor; James T Rutka
Journal:  Childs Nerv Syst       Date:  2006-09-02       Impact factor: 1.475

9.  Identification of transcriptional targets of the dual-function transcription factor/phosphatase eyes absent.

Authors:  Jennifer Jemc; Ilaria Rebay
Journal:  Dev Biol       Date:  2007-07-27       Impact factor: 3.582

10.  Conditional MN1-TEL knock-in mice develop acute myeloid leukemia in conjunction with overexpression of HOXA9.

Authors:  Hiroyuki Kawagoe; Gerard C Grosveld
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.